US Edition
Standardized Brain Cell Atlas to Accelerate Parkinson's and Alzheimer's Research
INDIANA UNIVERSITY SCHOOL OF MEDICINE, JUL 14 – Researchers used AI and proteomics to identify 30 potential 3-secretase targets, advancing precision Alzheimer’s therapies with a $41.6 million NIH grant backing this effort.
- Munich-Based researchers elucidated the mechanism by which 3-secretase selects its substrates, published this year in Nature Communications.
- In December 2024, the Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease received a five-year, $41.6 million grant renewal, the National Institute on Aging reported.
- The modular platform, combining optogenetics, chemistry, and AI, uses light-responsive domains with high-throughput screens for millisecond precision, broadening therapeutic target discovery.
- These insights, understanding 3-secretase substrate specificity could inform targeted therapies with reduced off-target effects, potentially refining treatments for Alzheimer’s disease.
- Future research with more diverse populations aims to develop diagnostic, preventive and treatment strategies through precision combination therapies optimized for disease subtypes, and could extend to other proteases and receptors, accelerating development of specific compounds.
23 Articles
23 Articles
Cambridge Times
Waterloo ChronicleAt the Library: ‘Tangles: A story about Alzheimer’s, my mother, and me’ by Sarah Leavitt
Sarah Leavitt’s ‘Tangles’ is a heartfelt graphic memoir that explores her mother’s experience with Alzheimer’s through honest storytelling and expressive illustration.
Standardized brain cell atlas to accelerate Parkinson's and Alzheimer's research
Researchers now have a powerful new way to understand the types of brain cells that are affected in neurodegenerative diseases and to uncover connections between conditions such as Parkinson's, Alzheimer's, and other forms of dementia.
Thanks to this international collaboration, researchers have begun to unravel the complex molecular landscape of neurodegeneration, which offers hope for early diagnosis and more specific therapies.
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging…
(Seoul = Yonhap News) Reporter Lee Ju-young = It will be used for biological basic research on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and aging, as well as early diagnosis and treatment development...
Coverage Details
Bias Distribution
- 44% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
